SCHEMBL5460600

SCHEMBL5460600

COC[C@H](NC(N)=S)c1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 4/20 0.42
IDO1 P14902 1/20 0.38
MEN1 O00255 1/20 0.38
CRHBP P24387 1/20 0.38
KMT2A Q03164 1/20 0.38
CRHR2 Q13324 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPK1 P28482 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
CNR1 P21554 1/20 0.37
UTS2R Q9UKP6 7/20 0.37
CNR2 P34972 1/20 0.37
LMNA P02545 2/20 0.36
AOC3 Q16853 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460826 0.84 MAPK1 (0.44) MEN1KMT2AMAPK1
SCHEMBL5456091 0.84 MAPK1 (0.44) MEN1KMT2AMAPK1
SCHEMBL5460850 0.84 TAS1R3 (0.48) RPS6KB1CRHBPCRHR2MAPK1
SCHEMBL5458231 0.83 ACACB (0.35) RPS6KB1IDO1MEN1KMT2AMAPK1
SCHEMBL5453071 0.83 SMN1; SMN2 (0.42) RPS6KB1IDO1MEN1KMT2ASMN1; SMN2
SCHEMBL5455776 0.80 RPS6KB1 (0.37) RPS6KB1MAPK1SLC6A2SLC6A4SLC6A3
SCHEMBL5455397 0.74 FFAR2 (0.38) IDO1SMN1; SMN2SLC6A2SLC6A4SLC6A3
SCHEMBL5469969 0.74 RAB9A (0.52) MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL27482886 0.74 MAPK1 (0.33) MAPK1
SCHEMBL27589463 0.70 GPR88 (0.55) MEN1KMT2ALMNAAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420679-B2 Aminothiazole derivatives and their use as CRF receptor ligands SANOFI (FR) 2013-04-16 US disclosed
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands SANOFI-AVENTIS (FR) 2007-12-06 US disclosed
CN-1167692-C Aminothiazole derivatives and their use as CRF receptor ligands ʥŵ��-�ϳ�ʵ���ҹ�˾ 2004-09-22 CN disclosed
EP-1200419-B1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI SYNTHELABO (FR) 2004-04-14 EP disclosed
US-6586456-B1 Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide SANOFI-SYNTHELABO (FR) 2003-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands CRH, CRHR1, CRHR2 RPS6KB1 1647/4885IDO1 3043/4885MEN1 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.